

Louis S Matza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/657675/publications.pdf>

Version: 2024-02-01

55
papers

1,460
citations

394421

19
h-index

345221

36
g-index

55
all docs

55
docs citations

55
times ranked

1945
citing authors

#	ARTICLE	IF	CITATIONS
1	Health state utilities associated with weight loss in type 2 diabetes and obesity. <i>Journal of Medical Economics</i> , 2022, 25, 14-25.	2.1	3
2	Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma. <i>PharmacoEconomics - Open</i> , 2022, 6, 367-376.	1.8	6
3	Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. <i>Patient</i> , 2022, 15, 367-377.	2.7	7
4	Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. <i>Quality of Life Research</i> , 2021, 30, 2033-2043.	3.1	7
5	Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 367.e7-367.e17.	1.6	4
6	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021, 24, 812-821.	0.3	39
7	Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. <i>Diabetes Therapy</i> , 2021, 12, 2387-2403.	2.5	10
8	A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities. <i>Diabetes Therapy</i> , 2021, 12, 2827-2856.	2.5	6
9	Assessing patient PREFERENCE between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 355-364.	4.4	31
10	Health state utilities associated with treatment for transfusion-dependent β^2 -thalassemia. <i>European Journal of Health Economics</i> , 2020, 21, 397-407.	2.8	9
11	Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy. <i>Diabetes Therapy</i> , 2020, 11, 319-330.	2.5	4
12	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. <i>Medical Decision Making</i> , 2020, 40, 897-911.	2.4	5
13	<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2231-2242.	1.8	8
14	Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). <i>Journal of Medical Economics</i> , 2020, 23, 978-984.	2.1	4
15	Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV. <i>Patient</i> , 2020, 13, 409-422.	2.7	6
16	Cover Image, Volume 22, Issue 3. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	4.4	0
17	Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ). <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 104.	1.9	0
18	Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS). <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 253-261.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). <i>Journal of Medical Economics</i> , 2019, 22, 936-944.	2.1	7
20	Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. <i>Drugs in R and D</i> , 2019, 19, 213-225.	2.2	10
21	Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. <i>Journal of Medical Economics</i> , 2019, 22, 806-813.	2.1	18
22	Health state utilities associated with post-surgical <i>Staphylococcus aureus</i> infections. <i>European Journal of Health Economics</i> , 2019, 20, 819-827.	2.8	15
23	Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. <i>Quality of Life Research</i> , 2019, 28, 2359-2372.	3.1	15
24	Health state utilities associated with treatment options for acute myeloid leukemia (AML). <i>Journal of Medical Economics</i> , 2019, 22, 567-576.	2.1	6
25	Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 139-146.	2.0	15
26	Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 1457-1464.	1.9	22
27	Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 44.	1.9	8
28	Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 43.	1.9	10
29	Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 971-979.	1.8	13
30	Challenges of Developing an Observable Parent-Reported Measure: A Qualitative Study of Functional Impact of ADHD in Children. <i>Value in Health</i> , 2017, 20, 828-833.	0.3	6
31	Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. <i>Quality of Life Research</i> , 2017, 26, 1785-1798.	3.1	7
32	Health State Utilities Associated with Glucose Monitoring Devices. <i>Value in Health</i> , 2017, 20, 507-511.	0.3	28
33	Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. <i>BMC Health Services Research</i> , 2017, 17, 774.	2.2	23
34	Preference for pharmaceutical formulation and treatment process attributes. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1385-1399.	1.8	56
35	Physician perceptions of GLP-1 receptor agonists in the UK. <i>Current Medical Research and Opinion</i> , 2016, 32, 857-864.	1.9	20
36	The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. <i>European Journal of Health Economics</i> , 2016, 17, 979-990.	2.8	17

#	ARTICLE	IF	CITATIONS
37	A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 192.	2.4	20
38	Acute and chronic impact of cardiovascular events on health state utilities. <i>BMC Health Services Research</i> , 2015, 15, 173.	2.2	47
39	Health state utilities associated with attributes of treatments for hepatitis C. <i>European Journal of Health Economics</i> , 2015, 16, 1005-1018.	2.8	35
40	Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2). <i>Patient</i> , 2015, 8, 433-443.	2.7	8
41	Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 90.	2.4	27
42	Health state utilities associated with adult attention-deficit/hyperactivity disorder. <i>Patient Preference and Adherence</i> , 2014, 8, 997.	1.8	7
43	Health state utilities for skeletal-related events secondary to bone metastases. <i>European Journal of Health Economics</i> , 2014, 15, 7-18.	2.8	21
44	Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 48.	2.4	18
45	The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition. <i>Quality of Life Research</i> , 2013, 22, 351-360.	3.1	12
46	A systematic literature review of cardiovascular event utilities. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 767-790.	1.4	14
47	Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force. <i>Value in Health</i> , 2013, 16, 461-479.	0.3	322
48	Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. <i>Patient Preference and Adherence</i> , 2013, 7, 855.	1.8	23
49	Development and validation of a patient-report measure of fatigue associated with depression. <i>Journal of Affective Disorders</i> , 2011, 134, 294-303.	4.1	19
50	Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. <i>European Journal of Health Economics</i> , 2011, 12, 219-230.	2.8	103
51	Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. <i>Current Medical Research and Opinion</i> , 2007, 23, 2051-2062.	1.9	21
52	Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 47.	2.4	56
53	Utilities and disutilities for type 2 diabetes treatment-related attributes. <i>Quality of Life Research</i> , 2007, 16, 1251-1265.	3.1	102
54	Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom. <i>Medical Decision Making</i> , 2005, 25, 56-70.	2.4	52

#	ARTICLE	IF	CITATIONS
55	The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2004, 25, 166-174.	1.1	104